VIDEO: FLT3 inhibitors appear superior to chemotherapy in FLT3-mutated AML
Click Here to Manage Email Alerts
Gilteritinib and quizartinib were well-tolerated and linked to improved survival and treatment response compared with salvage chemotherapy for relapsed or refractory FLT3 internal tandem duplication-mutated acute myeloid leukemia.
The data, which were presented at ASH Annual Meeting and Exposition, also showed that the responses to the two FLT3 inhibitors gilteritinib (Xospata, Astellas) and quizartinib (Daiichi Sankyo) and their side effect profiles were similar, according to Alexander E. Perl, MD, of Penn Medicine. However, Perl noted that this trial was not designed to directly compare these drugs.
“The advantage of a FLT3 inhibitor over salvage chemotherapy is true for either gilteritinib or quizartinib in a comparable population – indeed in this very high-risk population ... either of these drugs is superior to chemotherapy and should be the drug of choice in my mind,” Perl said. “We need to be careful about cross-study comparisons – there are some differences in terms of the responses ... but overall, these drugs are more similar than different in terms of their clinical benefit.”
Collapse
Perl AE, et al. Abstract 995. Presented at: ASH Annual Meeting and Exposition (virtual meeting); Dec. 5-8, 2020.
Click Here to Manage Email Alerts